Jaguar Health Q4 EPS $0.42 Down From $0.57 YoY, Sales $2.30B Beat $2.61M Estimate
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health (NASDAQ:JAGX) reported a decrease in Q4 EPS to $0.42 from $0.57 YoY, but sales surged to $2.30B, significantly beating the $2.61M estimate and marking a 70.45K percent increase from last year's $3.26M.
April 01, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's Q4 EPS decreased to $0.42 from $0.57 YoY, but sales soared to $2.30B, vastly outperforming the $2.61M estimate with a 70.45K percent increase from the previous year.
Despite the decrease in EPS, the significant beat on sales estimates and the extraordinary year-over-year sales growth are likely to be viewed positively by investors, potentially leading to a short-term increase in JAGX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100